STOCK TITAN

Virax Biolabs Group (VRAX) 424B Filings

VRAX NASDAQ

Here are the 424B prospectus supplements from Virax Biolabs Group Limited (VRAX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow VRAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRAX filings page.

Rhea-AI Summary

Virax Biolabs Group Limited (VRAX) has filed a resale prospectus covering up to 1,682,360 ordinary shares, all to be sold from time to time by existing security holders. These shares consist of 1,644,000 ordinary shares issuable upon exercise of new Series A and Series B preferred investment options and 38,360 shares issuable upon exercise of placement agent warrants. The new warrants have an exercise price of $6.00 per share and the placement agent warrants an exercise price of $7.50 per share, and become exercisable following shareholder approval of an authorized share increase on August 21, 2026, with expirations five years or eighteen months after September 3, 2026, as applicable.

The company will not receive proceeds from any resale of shares by the selling shareholders but may receive cash if the warrants are exercised, which it intends to use as working capital for general corporate purposes. Ordinary shares outstanding were 1,344,988 as of September 2, 2026; this is a baseline figure, not the amount being offered. Virax is a Cayman Islands holding company focused on T cell–based immune profiling and in vitro diagnostic technologies, qualifies as an emerging growth company and a foreign private issuer, and its ordinary shares trade on the Nasdaq Capital Market under the symbol VRAX.

Rhea-AI Summary

Virax Biolabs Group Limited (VRAX) updated its at-the-market equity program under its Form F-3 shelf registration, allowing the company to offer and sell up to $2,070,060.20 of ordinary shares from time to time through H.C. Wainwright & Co. under an existing At The Market Offering Agreement. This new capacity is based on General Instruction I.B.5 of Form F-3 and the company’s current public float. The update excludes approximately $3,658,152 of ordinary shares already sold under prior related prospectus supplements. Virax’s ordinary shares trade on the Nasdaq Capital Market under the symbol VRAX, and the company is relying on emerging growth company and foreign private issuer reporting accommodations.